Related Experiment Video
Updated: Jul 4, 2026
03:22
Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia
Published on: January 27, 2018
15.6K
Deuruxolitinib for Alopecia Areata
Alexander Robbins1, Mariana Phillips1,2
1Virginia Tech Carilion School of Medicine, Roanoke, VA, USA.
Skin Therapy Letter
|January 20, 2026
Summary
Deuruxolitinib, a new oral Janus kinase (JAK) inhibitor, is now approved for severe alopecia areata (AA). This review covers its mechanism, efficacy, and safety in treating this autoimmune hair loss condition.
Area of Science:
- Immunodermatology
- Autoimmune diseases
- Pharmacology
Background:
- Alopecia areata (AA) is an autoimmune disorder causing non-scarring hair loss, affecting 2% of the US population.
- The condition is driven by CD8 T-cells and involves key cytokines like interferon-gamma and interleukin-15.
- Janus kinase (JAK) signaling pathways are crucial for AA progression, making JAK inhibitors a therapeutic target.
Purpose of the Study:
- To review the mechanism of action of deuruxolitinib.
- To evaluate the clinical efficacy of deuruxolitinib in treating severe alopecia areata.
- To assess the safety profile of deuruxolitinib for alopecia areata patients.
Main Methods:
- Review of preclinical and clinical studies on deuruxolitinib.
- Analysis of data regarding JAK signaling pathways in alopecia areata.
- Examination of FDA approval documentation and related research.
Main Results:
- Deuruxolitinib is an oral JAK inhibitor approved in July 2024 for severe AA in adults.
- It represents the third oral JAK inhibitor available for severe AA, alongside baricitinib and ritlecitinib.
- The review details its specific mechanism, demonstrated clinical effectiveness, and safety data.
Conclusions:
- Deuruxolitinib offers a new therapeutic option for severe alopecia areata.
- Its approval highlights the success of targeting JAK signaling in treating this autoimmune condition.
- Further understanding of its long-term efficacy and safety is supported by ongoing research.
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.